申请人长期致力于肝移植原病复发的分子机制及防治研究，在该领域形成了具有自身特色的系统研究方向，主要学术成绩包括：1.发现一系列原病复发新型分子标记物及调控网络，突破传统形态学标准，创建基于分子分型的肝癌肝移植新标准；2.提出“供肝基因调控移植术后代谢微环境并参与原病复发”的全新理念，首次揭示供肝TCF7L2等在原病复发机制中的重要作用；3.进一步建立抗癌药物分子改性和两亲性高分子载药系统相结合的治疗新方法，提出应用纳米药物治疗肝移植原病复发新策略。以第一作者或通讯作者在Gut、Journal of Hepatology等发表SCI论文35篇（4篇IF>10分），入选教育部长江学者特聘教授和科技部中青年科技创新领军人才。作为主要完成人获得国家科技进步创新团队奖、一等奖、二等奖共3项。申请人拟开展移植肝代谢微环境介导原病复发的分子机制及靶向治疗研究，以期提高肝移植疗效。

The applicant has been engaged in the molecular mechanisms and interventions for primary disease recurrence after liver transplantation. His main scientific achievements are listed as follows: (1) Discovery of a series of biomarkers as well as the regulatory networks involved in primary disease recurrence, and establishment of a new set of recipient selection criteria based on molecular-phenotyping in liver transplantation for hepatocellular carcinoma; (2) Elucidation of the roles of donor genes (such as TCF7L2) in recipients’ primary disease recurrence after transplantation, providing insights to new therapeutic targets in the donor livers; (3) Establishment of a nanomaterial-based therapy which combines molecular modification of anti-cancer drugs and amphiphilic delivery vehicles, suggesting new strategies in the treatment of post-transplant recurrence. As the first author or corresponding author, the applicant has published 35 papers in SCI journals such as Gut and Journal of Hepatology (including 4 papers in journals with IF>10). The applicant was elected as “Distinguished Professor of Cheung Kong Scholars Program” of Ministry of Education, and “Science and Technology Innovation Talent” of Ministry of Science and Technology. He was awarded the Innovative Team Prize, the First-Class Prize and the Second-Class Prize of “National Scientific and Technological Progress Awards”. The applicant will study the molecular mechanisms by which liver graft metabolic micro-environment mediates the recurrence of primary diseases, and develop new molecular targeted therapy to improve the curative effect of liver transplantation.